Kawasaki Yuki, Hijioka Susumu, Nagashio Yoshikuni, Ohba Akihiro, Maruki Yuta, Takeshita Kotaro, Takasaki Tetsuro, Agarie Daiki, Hagiwara Yuya, Hara Hidenobu, Okamoto Kohei, Yamashige Daiki, Kondo Shunsuke, Morizane Chigusa, Ueno Hideki, Mizui Takahiro, Takamoto Takeshi, Nara Satoshi, Ban Daisuke, Esaki Minoru, Saito Yutaka, Hiraoka Nobuyoshi, Okusaka Takuji
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Digestive Disease Center, Showa University Koto Toyosu Hospital, Tokyo, Japan.
Endosc Ultrasound. 2024 Mar-Apr;13(2):115-122. doi: 10.1097/eus.0000000000000052. Epub 2024 Apr 5.
EUS tissue acquisition (EUS-TA) is the standard diagnostic method for solid pancreatic lesions (SPLs); however, there are few reports on EUS-TA results for SPLs ≤10 mm. Furthermore, given the recent advent of fine-needle biopsy, the current diagnostic accuracy of EUS-TA for SPLs ≤10 mm is unknown. This study aimed to evaluate the diagnostic accuracy and efficacy of EUS-TA for SPLs ≤10 mm.
We retrospectively analyzed the data of 109 patients with SPLs ≤10 mm who underwent EUS-TA. All patients underwent rapid on-site specimen evaluation.
The median tumor diameter was 8 mm (range, 2.5-10 mm), and the technical success rate was 99.1% (108/109). Adverse events were observed in 3 patients (2.8%). The diagnostic performance was as follows: sensitivity, 90.1% (64/71); specificity, 97.3% (36/37); accuracy, 92.6% (100/108); positive predictive value, 98.5% (64/65); and negative predictive value, 83.7% (36/43). Multivariate analysis revealed that the number of punctures (odds ratio, 7.03; 95% confidence interval, 1.32-37.5; = 0.023) and tumor type (odds ratio, 11.90; 95% confidence interval, 1.38-102.0; = 0.024) were independent risk factors for inaccurate EUS-TA results. The diagnostic accuracy of EUS-TA for pancreatic ductal adenocarcinoma was 87.5% (14/16). No EUS-TA-related needle-tract seeding was observed in patients with pancreatic ductal adenocarcinoma during the observation period.
EUS-TA for SPLs ≤10 mm showed adequate diagnostic accuracy and was safe for use with rapid on-site specimen evaluation in all cases.
超声内镜组织获取术(EUS-TA)是实体性胰腺病变(SPL)的标准诊断方法;然而,关于直径≤10 mm的SPL的EUS-TA结果的报道较少。此外,鉴于细针活检的近期出现,目前EUS-TA对直径≤10 mm的SPL的诊断准确性尚不清楚。本研究旨在评估EUS-TA对直径≤10 mm的SPL的诊断准确性和有效性。
我们回顾性分析了109例接受EUS-TA的直径≤10 mm的SPL患者的数据。所有患者均接受了快速现场标本评估。
肿瘤中位直径为8 mm(范围2.5 - 10 mm),技术成功率为99.1%(108/109)。3例患者(2.8%)观察到不良事件。诊断性能如下:敏感性90.1%(64/71);特异性97.3%(36/37);准确性92.6%(100/108);阳性预测值98.5%(64/65);阴性预测值83.7%(36/43)。多因素分析显示,穿刺次数(比值比,7.03;95%置信区间,1.32 - 37.5;P = 0.023)和肿瘤类型(比值比,11.90;95%置信区间,1.38 - 102.0;P = 0.024)是EUS-TA结果不准确的独立危险因素。EUS-TA对胰腺导管腺癌的诊断准确性为87.5%(14/16)。在观察期内,胰腺导管腺癌患者未观察到与EUS-TA相关的针道种植。
EUS-TA对直径≤10 mm的SPL显示出足够的诊断准确性,并且在所有病例中与快速现场标本评估一起使用是安全的。